Dr. Schadendorf on the Efficacy of Targeted Therapy Plus Checkpoint Inhibitors

Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.

There has been great progress in treating advanced melanoma, states Schadendorf. Checkpoint blockade has made contributions, giving long duration of responses and a median overall survivial of 3 years.

<<< View more from the World Congress of Melanoma